Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.
Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
EvOx Therapeutics harnesses the body’s own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable including those affecting the brain, as well as autoimmune diseases and cancers.
Incorporated in April 2016
Origin: Oxford University, Neuroscience
G-Nostics has identified SNPs that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.
Origin: Oxford University, Department of Pharmacology
Develop cutting edge software applications that uncover the relationships between genetic variation and human disease.
Help pharmaceutical companies de-risk the drug development process.
Incorporated in March 2014
Origin: Oxford University, Wellcome Trust Centre for Human Genetics
Intelligent Ultrasound develops and sells products and services that make medical ultrasound imaging a more effective diagnostic tool and help hospitals provide a better quality, more consistent ultrasound imaging service for their patients.
Incorporated in July 2012
Origin: Oxford University, Institute of Biomedical Engineering